EIF3M

Across TCGA pan-cancer cohorts, EIF3M Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EIF3M data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EIF3M Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EIF3M expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and BLCA are the cancer types where EIF3M Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.101	0.710	<.001	18	view →
UCEC	DFS	Median	II,III,IV	1.000	0.441	.024	14	view →
BLCA	OS	Median	IV	0.130	0.599	.002	12	view →
COAD	OS	Median	All	0.493	0.870	.013	8	view →
GBM	OS	Median	All	0.024	0.416	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	All	0.244	0.767	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EIF3M–HNSC (DFS)

Open the HNSC breakdown →